Tumor Response

The majority of patients experienced a reduction in tumor size with ENHERTU1

Best percent change from baseline in sum of diameters of target lesions by ICR1,a

Chart depicting that the majority of ENHERTU patients (n=168) experienced more than 30% partial response from baseline; only a small amount saw the progression of disease, 20% over the baseline. Chart depicting that the majority of ENHERTU patients (n=168) experienced more than 30% partial response from baseline; only a small amount saw the progression of disease, 20% over the baseline.
97.3%
DCR
Disease control rate1
DCR=CR+PR+SD
(n=179/184; 95% CI: 93.8, 99.1)
76.1%
CBR
Clinical benefit rate1
CBR=CR+PR+SD≥6 months
(n=140/184; 95% CI: 69.3, 82.1)
aNumbers based on patients treated with ENHERTU 5.4 mg/kg Q3W who had both baseline and postbaseline target lesions assessed by ICR (n=168).1 For each subject, the minimum (best) percent change from baseline in the sum of the diameters for all target lesions is represented by a vertical line.

 

DESTINY-Breast01
follow-up data

(June 2020 data cutoff)
Originally presented at SABCS 2020 with an encore at Miami Breast 2021

View Additional Data bold-arrow
Ready to learn more about ENHERTU?
CBR, clinical benefit rate; CI, confidence interval; CR, complete response; DCR, disease control rate; ICR, independent central review; PR, partial response; Q3W, every 3 weeks; SD, stable disease.